Skip to main content
MarketStoryBook

1801.HK in “GLP-1 Eats Everything”

Innovent Biologics, Inc.

Bull sideFadingExposure: not rated yet

Innovent commercializes mazdutide, an approved GLP-1/glucagon dual agonist for chronic weight management in China.

1801.HK impact map — “GLP-1 Eats Everything”

How this story travels from the headline to 1801.HK’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.

Loading 1801.HK impact map…

Price history, marked with story events

Oct 20, 2025 – Oct 19, 2026 · 247 sessions

Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions

Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…

Full story

GLP-1 Eats Everything

Appetite suppression as a macro variable.

BULL side — Innovent commercializes mazdutide, an approved GLP-1/glucagon dual agonist for chronic weight management in China.

Read the full GLP-1 Eats Everything story

Bull side

3 stories
  • America Imports the World's Drug Prices

    1801.HK in “America Imports the World's Drug Prices”

    StableExposure: not rated yet

    US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.

    Innovent's portfolio of lower-cost biosimilars in oncology and immunology can support payer demands for credible alternatives to expensive biologic brands.

  • 1801.HK in “GLP-1 Eats Everything”

    FadingExposure: not rated yet
    Viewing

    Appetite suppression as a macro variable.

    Innovent commercializes mazdutide, an approved GLP-1/glucagon dual agonist for chronic weight management in China.

  • China Becomes Pharma's Global R&D Engine

    1801.HK in “China Becomes Pharma's Global R&D Engine”

    FadingExposure: not rated yet

    Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.

    Its broad oncology and metabolic pipeline offers multiple opportunities for overseas licensing and commercialization.

Bear side

0 stories

No bear-side stories for 1801.HK yet.